Enrique Miranda-Peralta

Enrique Miranda-Peralta

Auto-generated profile, based on publicly available information

Enrique Miranda-Peralta

A Laboratorio de Biología Molecular , Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga" , Ciudad de México , Mexico

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CBCarolina Bekker-Mendez
Carolina Bekker-Mendez
EMEnrique Miranda-Peralta
Enrique Miranda-Peralta
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
IOIrma Olarte-Carrillo
Irma Olarte-Carrillo
FGFrancisco Xavier Guerra-Castillo
Francisco Xavier Guerra-Castillo
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Mexico has one of the highest incidences of childhood leukemia worldwide and significantly higher mortality rates for this disease compared with other countries. One possible cause is the high prevalence of gene rearrangements associated with the etiology or with a poor prognosis of childhood acute lymphoblastic leukemia (ALL). The aims of this multicenter study were to determine the prevalence of the four most common gene rearrangements [ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, andMLLrearrangements] and to explore their relationship with mortality rates during the first year of treatment in ALL children from Mexico City. Patients were recruited from eight public hospitals during 2010–2012. A total of 282 bone marrow samples were obtained at each child’s diagnosis for screening by conventional and multiplex reverse transcription polymerase chain reaction to determine the gene rearrangements. Gene rearrangements were detected in 50 (17.7%) patients.ETV6-RUNX1was detected in 21 (7.4%) patients,TCF3-PBX1in 20 (7.1%) patients,BCR-ABL1in 5 (1.8%) patients, andMLLrearrangements in 4 (1.4%) patients. The earliest deaths occurred at months 1, 2, and 3 after diagnosis in patients withMLL, ETV6-RUNX1, andBCR-ABL1gene rearrangements, respectively. Gene rearrangements could be related to the aggressiveness of leukemia observed in Mexican children.

1 October 2008 in Leukemia Research
Verified
Journal Article
Closed access
SJS. Jiménez-Morales
S. Jiménez-Morales
EME. Miranda-Peralta
E. Miranda-Peralta
YSY. Saldaña-Alvarez
Y. Saldaña-Alvarez
PPP. Perez-Vera
P. Perez-Vera
RPR. Paredes-Aguilera
R. Paredes-Aguilera
LOLorena Orozco
Lorena Orozco

14 December 2016 in Hematology
Verified
Journal Article
Closed access
IOIrma Olarte
Irma Olarte
CPChristian Omar Ramos Peñafiel
Christian Omar Ramos Peñafiel
EPE. Miranda Peralta
E. Miranda Peralta
EFE. Rozen Fuller
E. Rozen Fuller
JIJ. J. Kassack Ipiña
J. J. Kassack Ipiña
ATADOLFO MARTINEZ TOVAR
ADOLFO MARTINEZ TOVAR
Objectives: Acute lymphoblastic leukemia (ALL) is a clonal disease that accounts for 20% of acute leukemias in adults. A high percentage of adult patients (ranging from 70 to 80%) reach complete remission; however, the 5-year survival rate is only 20–40%. One of the main obstacles to treatment success is the drug resistance of leukemic cells. Therefore, our research group analyzed the ABCB1 and ABCG2 gene expression levels in 61 patients diagnosed with ALL and assessed whether the levels affected the clinical parameters and 40-month survival rate. Methods: The ABCB1 and ABCG2 gene expression levels were analyzed using real-time polymerase chain reaction in 61 patients diagnosed with ALL and 99 healthy donors as controls. The association between ABCB1 and ABCG2 gene expression levels and clinical variables was determined using the Chi-square test and Fisher’s exact test. Overall survival (OS) was determined using the Kaplan–Meier method. Results: The results showed high ABCB1 and ABCG2 gene levels, which were 4.5 and 2.3 times the levels of healthy donors, respectively. A total of 52% of the study patients expressed high ABCB1 levels and were significantly associated with the high-risk patient group and a decreased 40-month survival rate of 78%. Only 49% of the patients expressed high ABCG2 gene levels. No association was found between the clinical parameters and the ABCG2 gene expression levels. Conclusions: Early detection of ABCB1 gene expression levels could be important for the diagnosis and monitoring of ALL patients.

10 March 2003 in Cancer Letters
Verified
Journal Article
Closed access
PDF file
AEAdriana Estrada-Bernal
Adriana Estrada-Bernal
CMCriselda Mendoza-Milla
Criselda Mendoza-Milla
JVJosé Luis Ventura-Gallegos
José Luis Ventura-Gallegos
LLLucia Nikolaia López-Bojórquez
Lucia Nikolaia López-Bojórquez
EMEnrique Miranda-Peralta
Enrique Miranda-Peralta
AZAlejandro Zentella-Dehesa
Alejandro Zentella-Dehesa

1 January 2006 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JMJuan José Montesinos
Juan José Montesinos
ESElizabeth Sánchez-Valle
Elizabeth Sánchez-Valle
EFEugenia Flores-Figueroa
Eugenia Flores-Figueroa
GMGuadalupe Martínez-Jaramillo
Guadalupe Martínez-Jaramillo
PFPatricia Flores-Guzmán
Patricia Flores-Guzmán
HMHector Mayani
Hector Mayani
One has previously characterized two different hematopoietic cell populations (obtained by negative-selection) from normal bone marrow. Population I was enriched for CD34+ Lin- cells, whereas Population II was enriched for CD34+ CD38- Lin- cells. Both populations showed elevated proliferation and expansion potentials in serum-free liquid cultures, supplemented with a combination of eight different cytokines, with the latter displaying more immature features than the former. One has also characterized the chronic myeloid leukemia (CML) counterparts of these two populations and demonstrated functional deficiencies in terms of their growth in culture. In keeping with this line of research, the goal of the present study was to obtain the same two populations (Populations I and II) from acute myeloid leukemia (AML) bone marrow and to characterize their biological behavior under the same culture conditions. The results demonstrated that AML-derived Populations I and II were unable to proliferate in culture conditions that allowed significant proliferation of Populations I and II from normal marrow. Population I from AML also showed a deficient expansion capacity; in contrast, Population II cells were able to expand to a similar extent to the one observed for Population II from normal marrow. Both normal and AML populations were highly sensitive to the inhibitory effects of TNF-alpha; interestingly, whereas in normal fractions TNF-alpha showed a more pronounced inhibitory effect on more mature cells (Population I), this cytokine inhibited proliferation and expansion of AML Populations I and II in a similar degree. It is noteworthy that the functional deficiencies observed in AML cells were even more pronounced than those previously reported for cultures of CML cells. The results reported here may be of relevance considering the interest by several groups in developing methods for the in vitro purging of leukemic cells, as part of protocols for autologous transplantation of hematopoietic cells in leukemic patients.

14 June 2012 in Oncology Letters
Verified
Journal Article
Open access
PDF file
ELEdgar Ledesma-Martínez
Edgar Ledesma-Martínez
CPC. Pérez-Cordero
C. Pérez-Cordero
YCY. Córdova-Galaviz
Y. Córdova-Galaviz
GSG. Sánchez-Tellez
G. Sánchez-Tellez
SHSara Huerta-Yepez
Sara Huerta-Yepez
ESEdelmiro Santiago-Osorio
Edelmiro Santiago-Osorio
Acute myeloid leukaemia results from the neoplastic transformation of haematopoietic stem cells. Although advances have been made in its treatment, the mortality rate remains high. As a result, therapeutic alternatives continue to be explored. In this study, we present evidence that suggests that casein, the principal protein in milk, possesses significant antileukaemic properties. We investigated whether casein inhibited the in vitro proliferation and induced the apoptosis of the mouse myelomonocytic leukaemia cell line WEHI-3. By contrast, under identical conditions, casein markedly promotes the proliferation of mouse normal mononuclear bone marrow cells. Since the selective elimination of leukaemia cells is an ideal therapeutic strategy, we also evaluated the antileukaemic potential of casein in vivo. The results showed that casein increases the survival of mice bearing WEHI-3-induced tumours, suggesting that this molecule is also capable of inhibiting the proliferation of these cells in vivo. The evidence that casein inhibited cell proliferation and induced apoptosis in leukaemia cells in vitro, but increased survival in vivo in a leukaemia mouse model, indicates that casein may be useful in leukaemia therapy.